These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 25399713)

  • 21. Stratified medicine: making it happen.
    Foot E
    Drug Discov Today; 2011 Oct; 16(19-20):848-9. PubMed ID: 21920455
    [No Abstract]   [Full Text] [Related]  

  • 22. Should pharmacogenetics be incorporated in major depression treatment? Economic evaluation in high- and middle-income European countries.
    Olgiati P; Bajo E; Bigelli M; De Ronchi D; Serretti A
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Jan; 36(1):147-54. PubMed ID: 21911028
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of plasmid-derived external quality control samples in pharmacogenetic testing.
    van der Straaten T; Swen J; Baak-Pablo R; Guchelaar HJ
    Pharmacogenomics; 2008 Sep; 9(9):1261-6. PubMed ID: 18781854
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Financial determinants of outcomes in molecular testing.
    Ross JS
    Arch Pathol Lab Med; 1999 Nov; 123(11):1071-5. PubMed ID: 10539911
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Beyond the clinic: 'direct-to-consumer' genomic profiling services and pharmacogenomics.
    Prainsack B; Vayena E
    Pharmacogenomics; 2013 Mar; 14(4):403-12. PubMed ID: 23438887
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness model of use of genetic testing as an aid in assessing the likely benefit of aspirin therapy for primary prevention of cardiovascular disease.
    Shiffman D; Slawsky K; Fusfeld L; Devlin JJ; Goss TF
    Clin Ther; 2012 Jun; 34(6):1387-94. PubMed ID: 22560621
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe.
    van den Akker-van Marle ME; Gurwitz D; Detmar SB; Enzing CM; Hopkins MM; Gutierrez de Mesa E; Ibarreta D
    Pharmacogenomics; 2006 Jul; 7(5):783-92. PubMed ID: 16886902
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of genotype-guided warfarin therapy for anticoagulation in elderly patients with atrial fibrillation.
    Leey JA; McCabe S; Koch JA; Miles TP
    Am J Geriatr Pharmacother; 2009 Aug; 7(4):197-203. PubMed ID: 19766951
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An introduction to cost-effectiveness and cost-benefit analysis of pharmacogenomics.
    Phillips KA; Veenstra D; Van Bebber S; Sakowski J
    Pharmacogenomics; 2003 May; 4(3):231-9. PubMed ID: 12718713
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A cost-effectiveness model of genetic testing for the evaluation of families with hypertrophic cardiomyopathy.
    Ingles J; McGaughran J; Scuffham PA; Atherton J; Semsarian C
    Heart; 2012 Apr; 98(8):625-30. PubMed ID: 22128210
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-utility analysis of genetic screening in families of patients with germline MUTYH mutations.
    Nielsen M; Hes FJ; Vasen HF; van den Hout WB
    BMC Med Genet; 2007 Jul; 8():42. PubMed ID: 17605803
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical utility of pharmacogenetic testing in compounding pharmacy.
    Fichter B; Heintzelman T; Hurst S; Fitzsimmons D; Mailloux C
    Int J Pharm Compd; 2013; 17(6):452-7. PubMed ID: 24579294
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular medicine: how, what, and when?
    Woodcock J
    Clin Pharmacol Ther; 2007 Oct; 82(4):376-8. PubMed ID: 17851578
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacogenetics in heart failure: promises and challenges.
    de Boer RA; van der Harst P; van Veldhuisen DJ; van den Berg MP
    Expert Opin Pharmacother; 2009 Aug; 10(11):1713-25. PubMed ID: 19558337
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetics and cardiovascular disease: the impact of molecular diagnosis.
    Vengoechea J; McKelvey KD
    J Ark Med Soc; 2013 Apr; 109(11):230-2. PubMed ID: 23691714
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model.
    Wordsworth S; Leal J; Blair E; Legood R; Thomson K; Seller A; Taylor J; Watkins H
    Eur Heart J; 2010 Apr; 31(8):926-35. PubMed ID: 20299350
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Economic opportunities and challenges for pharmacogenomics.
    Deverka PA; Vernon J; McLeod HL
    Annu Rev Pharmacol Toxicol; 2010; 50():423-37. PubMed ID: 20055709
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of pharmacogenetic testing to predict treatment response to angiotensin-converting enzyme inhibitor.
    Costa-Scharplatz M; van Asselt AD; Bachmann LM; Kessels AG; Severens JL
    Pharmacogenet Genomics; 2007 May; 17(5):359-68. PubMed ID: 17429318
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Legal implications of pharmacogenomics regarding drug trials, drug labeling, and genetic testing for drug prescription: an international approach.
    Mandry T
    Food Drug Law J; 2004; 59(4):519-35. PubMed ID: 15875348
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacogenomic testing: the cost factor.
    Wedlund PJ; de Leon J
    Pharmacogenomics J; 2001; 1(3):171-4. PubMed ID: 11908752
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.